多组分运动干预对认知功能认知障碍患者的比较有效性:系统性审查和网络元分析
Ziyu Deng1, Deqing Zeng2, Yuxuan Zhang3
1School of Nursing, Shanghai Jiao Tong University, Shanghai, Huangpu District, China.
Journal of clinical nursing
|August 8, 2025
概括
有氧运动加上平衡和灵活性训练对全球认知最好,而有氧运动加上抵抗训练可以改善认知障碍患者的执行功能.
科学领域:
- 神经学 神经学
- 老年学是指老年学的学科.
- 运动科学 运动科学
背景情况:
- 多元组件运动是一种流行的非药物治疗认知障碍的方法.
- 运动组合的变化导致不一致的认知效应.
- 确定最佳的运动组合对于认知健康至关重要.
研究的目的:
- 为了比较和排名不同多组分运动干预在认知障碍患者的认知效果的有效性.
- 为了确定增强认知功能的最有益的运动组合.
主要方法:
- 在多个数据库 (PubMed,科学网,Embase,Cochrane,SPORTDiscus,PsycInfo) 进行系统搜索,截至2025年4月.
- 包括针对认知障碍的多组分运动干预的随机对照试验.
- 应用双向和网络元分析,使用随机效应模型来评估全球认知,执行功能和记忆等结果.
主要成果:
- 分析了25项试验,共有2298名参与者.
- 多组件运动对全球认知 (SMD=0.59) 和执行功能 (SMD=0.28) 产生了显著的益处.
- 有氧运动加上平衡和灵活性训练在全球认知方面表现出最高的有效性 (SMD=1.07),而有氧运动加上抵抗运动对执行功能来说是最佳的 (SMD=0.56).
- 没有观察到对记忆的显著影响.
结论:
- 有氧运动与平衡和灵活性训练相结合,是改善全球认知的最有效的干预措施.
- 有氧运动与抵抗训练相结合,对认知障碍患者的执行功能产生最佳影响.
- 研究结果指导临床专业人员设计针对性干预措施,以保护认知.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
01:30Cognitive Development During Adulthood
275
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
275
01:22Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261